Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIntelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
2.0501 USD -0.20 ( 8.88%)
Last update at 2026-11-11T20:24:00Z
VOLUME
83996
Market Cap
7.23M

Momentum Score

…

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.01
Low
2.25
High
52 Week Price Range
2.16
Low
44.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Intelligent Bio Solutions Inc. (NASDAQ: INBS) are limited; the company positions itself in molecular diagnostics and lab automation for rapid infectious-disease and oncology testing. Long-term growth may be driven by commercial adoption, clinical validation, regulatory clearances and partnerships; investors may find exposure to diagnostics innovation appealing if the company scales.

Key risks include limited operating and clinical disclosure, potential failure to obtain regulatory approval, the need for additional financing, execution risk in commercialization and low liquidity as a microcap.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.25
Dividend Yield
-
Revenue TTM
2.83M
Revenue Per Share
3.29
Gross Profit TTM
0.33M
Debt / Equity
0.20
ROE
-118.96%
Net Debt
-8.24M
ROCE
-108.42%
Diluted EPS TTM
-29.82

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -8.33M -8.33M -8.52M -3.16M -7.39M
Minority interest 0.03M 0.03M 0.02M 0.03M 0.06M
Net income -8.31M -8.31M -11.02M -3.71M -7.34M
Selling general administrative 4.92M 4.92M 3.71M 2.43M 3.55M
Gross profit 0.33M 0.00M 1.98M 0.19M -
Reconciled depreciation 0.97M 0.00M - - -
Ebit -8.34M -8.34M -5.57M -2.71M -6.73M
Ebitda -8.32M -8.30M -7.15M -2.56M -6.67M
Depreciation and amortization 0.01M - -1.58M 0.15M 0.06M
Operating income -8.34M -8.34M -5.57M -2.71M -6.73M
Other operating expenses 8.34M 8.34M 7.03M 2.83M 6.73M
Interest expense 0.01M 0.01M 1.09M 0.46M 0.66M
Tax provision - 0.00M 0.00M 0.00M -
Interest income 0.01M 0.01M 0.01M 0.00M 0.00M
Net interest income -0.21M 0.01M -1.08M -0.46M -0.66M
Income tax expense -0.03M -0.03M 2.50M 0.55M -0.06M
Total revenue 1.26M 0.00M 1.98M 0.19M 0.00M
Total operating expenses 8.34M 8.34M 7.03M 2.83M 6.73M
Cost of revenue 0.93M 0.00M - - -
Total other income expense net 0.00M 0.00M -2.95M -0.46M -0.66M
Net income from continuing ops -10.66M -8.33M -7.06M -3.16M -7.39M
Net income applicable to common shares -10.63M -8.31M -7.04M -3.16M -7.34M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 12.35M 12.35M 20.40M 2.48M 2.33M
Intangible assets 5.26M - - - -
Other current assets 0.75M 0.16M 3.81M 0.01M 2.04M
Total liab 5.81M 5.81M 6.85M 7.69M 6.31M
Total stockholder equity 6.62M 6.62M 13.61M -5.19M -4.62M
Deferred long term liab - - 0.50M - -
Other current liab 0.20M 1.11M -0.02M 2.07M 0.27M
Common stock 0.15M 0.15M 0.14M 2.85M 1.95M
Capital stock 0.02M 0.15M 0.15M 20.18M 16.98M
Retained earnings -31.18M -31.18M -24.32M -15.83M -12.67M
Other liab 0.02M 1.14M 3.17M - -
Other assets - 1.09M 3.65M - -
Cash 8.24M 8.24M 12.57M 0.43M 0.20M
Total current liabilities 4.66M 4.66M 3.68M 7.69M 6.31M
Current deferred revenue 2.84M 2.84M 2.10M - -
Net debt -8.24M -8.24M -12.57M 4.71M 4.93M
Short term debt 0.58M - 0.14M 5.13M 5.13M
Short long term debt 0.35M - - 5.13M 5.13M
Short long term debt total 1.34M - - 5.13M 5.13M
Other stockholder equity 38.44M 38.44M 38.44M -9.17M -8.71M
Property plant equipment 1.24M 0.39M - - -
Total current assets 10.87M 10.87M 16.39M 2.34M 2.33M
Long term investments - - 0.00M 0.14M -
Net tangible assets -1.46M 6.62M 15.04M -5.21M -19.01M
Net receivables 1.88M 2.47M 3.21M 0.02M 0.09M
Long term debt 0.40M - - - -
Inventory 0.98M - -3.21M 1.88M -
Accounts payable 1.63M 0.72M 1.47M 0.48M 0.90M
Accumulated other comprehensive income -0.79M -0.79M -0.66M -0.36M -0.22M
Non currrent assets other 1.09M 1.09M 4.01M - -
Non current assets total 1.48M 1.48M 4.01M 0.14M 0.00M
Capital lease obligations 0.58M - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.69M -0.88M -0.01M -0.01M -0.01M
Change to liabilities 1.12M 0.24M -0.97M 2.41M -0.13M
Total cashflows from investing activities -0.69M -0.88M -0.88M -0.01M -0.01M
Net borrowings - - - -0.15M -0.15M
Total cash from financing activities 1.44M 1.44M 23.40M 0.73M 5.32M
Change to operating activities -0.40M 0.37M -3.97M 0.10M 0.10M
Net income -8.33M -8.33M -7.06M -3.16M -7.39M
Change in cash -4.34M -4.34M 12.15M 0.23M -0.22M
Begin period cash flow 12.57M 12.57M 0.43M 0.20M 0.42M
End period cash flow 8.24M 8.24M 12.57M 0.43M 0.20M
Total cash from operating activities -3.36M -3.36M -11.30M -0.50M -5.58M
Issuance of capital stock 2.78M 0.00M 24.89M 1.00M -
Depreciation 0.97M 0.97M 0.97M 0.97M -
Other cashflows from investing activities - -0.50M -0.50M -0.50M -0.50M
Change to inventory -2.50M -0.35M 1.03M -0.10M -
Change to account receivables 2.50M 1.83M -1.03M 0.05M 0.12M
Sale purchase of stock -0.01M - - - -
Other cashflows from financing activities -0.88M -0.88M 1.80M -0.12M 5.32M
Change to netincome 2.21M 2.51M 0.68M 0.04M 1.89M
Capital expenditures 0.38M 0.38M 0.38M 0.38M 0.38M
Change in working capital 2.44M 2.44M -4.94M 1.40M -0.13M
Stock based compensation 0.26M 0.00M - 0.90M 1.95M
Other non cash items 2.54M 2.54M 0.70M 0.36M 1.89M
Free cash flow -3.74M -3.74M -11.30M -0.50M -5.58M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INBS
Intelligent Bio Solutions Inc.		 -0.20
8.88%		 2.05 - - 3.51 2.64 3.50 -0.71
ABT
Abbott Laboratories		 -1.17
1.06%		 109.29 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.02
0.02%		 101.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -5.50
1.70%		 318.79 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

142 West 57th Street, New York, NY, United States, 10019

(646) 828-8258

https://ibs.inc

51

Name Title Year Born
Mr. Harry Simeonidis Pres & CEO 1967
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law Chief Financial Officer 1962
Ms. Victoria Gavrilenko Operations Mang. 1983
Mr. Alex Arzeno VP of Investor Relations NA
Mr. Harry Simeonidis President & CEO 1967
Ms. Victoria Gavrilenko Operations Manager 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…